You are here

340B

The 340B Program Reached $54 Billion in 2022—Up 22% vs. 2021

The 340B Program Reached $54 Billion in 2022—Up 22% vs. 2021

Drug Channels

Flag link:

For 2023, Five For-Profit Retailers and PBMs Dominate an Evolving 340B Contract Pharmacy Market

For 2023, Five For-Profit Retailers and PBMs Dominate an Evolving 340B Contract Pharmacy Market

Drug Channels

Express Scripts

Unitedhealth Group

Flag link:

Astellas to withhold prostate cancer drug from contract pharmacies

Astellas to withhold prostate cancer drug from contract pharmacies

Beckers Hospital Review

prostate cancer

Flag link:

Teva to stop sending 340B-discounted drugs to contract pharmacies

Teva to stop sending 340B-discounted drugs to contract pharmacies

Beckers Hospital Review

Teva Pharmaceutical

Flag link:

The Inflation Reduction Act: 10 Predictions About Market Access and Drug Channels

The Inflation Reduction Act: 10 Predictions About Market Access and Drug Channels

Drug Channels

Inflation Reduction Act

Medicare Part D

Flag link:

PhRMA-backed alliance says it wants to 'modernize' the 340B program. Critics say the changes will only limit access

PhRMA-backed alliance says it wants to 'modernize' the 340B program. Critics say the changes will only limit access

Endpoints

Flag link:

J&J to impose new limits on 340B access after industry court win

J&J to impose new limits on 340B access after industry court win

Endpoints

Flag link:

AstraZeneca, Novo Nordisk and Sanofi score 340B-related appeals court win over HHS

AstraZeneca, Novo Nordisk and Sanofi score 340B-related appeals court win over HHS

Endpoints

Flag link:

The 340B Program Climbed to $44 Billion in 2021—With Hospitals Grabbing Most of the Money

The 340B Program Climbed to $44 Billion in 2021—With Hospitals Grabbing Most of the Money

Drug Channels

Flag link:

340B entities face increased challenges in a shifting regulatory and enforcement landscape

340B entities face increased challenges in a shifting regulatory and enforcement landscape

MedCity News

Flag link:

How health systems are responding to 340B discount restrictions

How health systems are responding to 340B discount restrictions

Beckers Hospital Review

Flag link:

Ballooning 340B market reaches almost 15% of 2021 US pharma sales, IQVIA finds

Ballooning 340B market reaches almost 15% of 2021 US pharma sales, IQVIA finds

Endpoints

Flag link:

The 340B Noncompliance Data Gap Leaves Drug Manufacturers in the Dark

The 340B Noncompliance Data Gap Leaves Drug Manufacturers in the Dark

Drug Channels

Flag link:

Gilead to limit 340B discounts for hepatitis C drugs

Gilead to limit 340B discounts for hepatitis C drugs

Beckers Hospital Review

Gilead Sciences

Flag link:

AstraZeneca scores another industry victory over the federal government in 340B litigation

AstraZeneca scores another industry victory over the federal government in 340B litigation

Endpoints

Flag link:

GSK joins a crowd of pharma companies restricting sales under federal program

GSK joins a crowd of pharma companies restricting sales under federal program

Endpoints

Flag link:

Baker's dozen: Pfizer joins 12 peers in restricting sales of discounted drugs under a federal program

Baker's dozen: Pfizer joins 12 peers in restricting sales of discounted drugs under a federal program

Endpoints

Flag link:

Not cheaper by the dozen: Bristol Myers becomes the 12th pharma company to restrict 340B sales

Not cheaper by the dozen: Bristol Myers becomes the 12th pharma company to restrict 340B sales

Endpoints

Bristol Myers Squibb

Flag link:

Amgen halts some drug discounts for safety net hospitals as SCOTUS takes on 340B case

Amgen halts some drug discounts for safety net hospitals as SCOTUS takes on 340B case

Endpoints

Flag link:

UCB to restrict 340B discounts to hospitals using community pharmacies

UCB to restrict 340B discounts to hospitals using community pharmacies

Beckers Hospital Review

Flag link:

Pages